艾迪与康莱特注射液联合化疗治疗非小细胞肺癌的成本-效果分析  

Cost-effectiveness Analysis of Aidi Injection or Kailaite Injection Combined with Chemotherapy in the Treatment of Nonsmall-cell Lung Cancer

作　　者：刘桂玲[1] 徐国成[1] 

机构地区：[1]长春中医药大学研究生学院,长春130117

出　　处：《中国药房》2013年第48期4574-4576,共3页China Pharmacy

摘　　要：目的:比较艾迪注射液与康莱特注射液联合化疗治疗非小细胞肺癌(NSCLC)的经济学效果。方法:将51例NSCLC患者随机分为A组(艾迪注射液联合化疗治疗组,27例)和B组(康莱特注射液联合化疗治疗组,24例),观察两组的疗效,并运用药物经济学评价方法比较其成本-效果。结果:A组总有效率为44.4%,治疗成本为23 772.5元;B组总有效率为37.5%,治疗成本为23 254.0元,两组成本-效果比(C/E)分别为535.4和620.0。以B组为参照的增量成本-效果比(ΔC/ΔE)为75.1。结论:两组治疗方案比较,艾迪注射液联合化疗治疗NSCLC是更为经济、有效的治疗方案。OBJECTIVE： To compare the pharmacoeconomical effectiveness of Aidi injection or Kailaite injection combined with chemotherapy for nonsmall-cell lung cancer （NSCLC）. METHODS： 51 NSCLC patients were randomly divided into group A （Aidi injection combined with chemotherapy group, 27 cases） and group B （Kailaite injection combined with chemotherapy, 24 cases）. Therapeutic efficacies of 2 groups were observed, and cost-effectiveness of them was compared with pharmacoeconomics. RESULTS： Effective rate and cost of group A were 44.4% and 23 772.5 yuan; those of group B were 37.5% and 23 254.0 yuan. Cost-effectiveness （C/E） ratio of 2 groups were 535.4 and 620.0. The incremental △C/△E of group A was 75.1 to group B. CONCLUSIONS： Aidi injection combined with chemotherapy is more economical and effective than Kailaite injection combined with chemotherapy in the treatment of NSCLC.

关 键 词：中药 化疗 非小细胞肺癌 成本-效果分析 艾迪注射液 康莱特注射液 

分 类 号：R956[医药卫生—药学]